QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
QQQ   315.68 (+0.95%)
AAPL   162.36 (+0.99%)
MSFT   284.05 (+1.26%)
META   207.84 (+1.21%)
GOOGL   100.89 (-0.49%)
AMZN   102.00 (+1.75%)
TSLA   195.28 (+0.72%)
NVDA   273.83 (+1.48%)
NIO   10.46 (+6.41%)
BABA   103.38 (+3.46%)
AMD   97.88 (+1.86%)
T   19.08 (+0.42%)
F   12.29 (+1.99%)
MU   63.09 (-0.71%)
CGC   1.76 (-2.76%)
GE   94.05 (-0.01%)
DIS   98.10 (+1.27%)
AMC   4.97 (-0.60%)
PFE   40.38 (+0.32%)
PYPL   74.39 (+0.28%)
NFLX   338.43 (+1.93%)
NASDAQ:EDIT

Editas Medicine - EDIT Stock Forecast, Price & News

$7.03
-0.38 (-5.13%)
(As of 03/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$7.00
$7.52
50-Day Range
$7.03
$11.53
52-Week Range
$7.00
$21.59
Volume
2.00 million shs
Average Volume
1.75 million shs
Market Capitalization
$484.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.33

Editas Medicine MarketRank™ Forecast

Analyst Rating
Hold
2.21 Rating Score
Upside/​Downside
118.1% Upside
$15.33 Price Target
Short Interest
Bearish
29.93% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.84
Upright™ Environmental Score
News Sentiment
0.26mentions of Editas Medicine in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$89,105 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.95) to ($2.94) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.31 out of 5 stars

Medical Sector

276th out of 1,009 stocks

Biological Products, Except Diagnostic Industry

52nd out of 166 stocks


EDIT stock logo

About Editas Medicine (NASDAQ:EDIT) Stock

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

EDIT Stock News Headlines

BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
CRISPR Cas9 Market 2023 Size and Forecast to 2030
CRISPR Cas9 Market to 2023-2028
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Editas Medicine Earnings Preview
3 No-Brainer Stocks to Buy Right Now for Less Than $25
Why Editas Medicine's Shares Jumped This Week
Is Editas Medicine Stock a Buy Now?
See More Headlines
Receive EDIT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.

EDIT Company Calendar

Last Earnings
2/22/2023
Today
3/30/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EDIT
Fax
N/A
Employees
264
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$15.33
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+117.2%
Consensus Rating
Hold
Rating Score (0-4)
2.21
Research Coverage
14 Analysts

Profitability

Net Income
$-220,430,000.00
Net Margins
-1,118.32%
Pretax Margin
-1,118.26%

Debt

Sales & Book Value

Annual Sales
$19.71 million
Book Value
$5.25 per share

Miscellaneous

Free Float
68,073,000
Market Cap
$486.93 million
Optionable
Optionable
Beta
1.90

Key Executives

  • Gilmore O’Neill
    President, Chief Executive Officer & Director
  • Harry R. Gill
    Senior Vice President-Operations
  • Michelle RobertsonMichelle Robertson
    Chief Financial Officer & Treasurer
  • Bruce E. EatonBruce E. Eaton
    Executive VP, Chief Business & Technology Officer
  • Mark S. Shearman
    Chief Scientific Officer & Executive VP













EDIT Stock - Frequently Asked Questions

Should I buy or sell Editas Medicine stock right now?

14 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Editas Medicine in the last twelve months. There are currently 2 sell ratings, 7 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EDIT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EDIT, but not buy additional shares or sell existing shares.
View EDIT analyst ratings
or view top-rated stocks.

What is Editas Medicine's stock price forecast for 2023?

14 Wall Street research analysts have issued 12 month price targets for Editas Medicine's shares. Their EDIT share price forecasts range from $7.00 to $35.00. On average, they anticipate the company's stock price to reach $15.33 in the next twelve months. This suggests a possible upside of 117.2% from the stock's current price.
View analysts price targets for EDIT
or view top-rated stocks among Wall Street analysts.

How have EDIT shares performed in 2023?

Editas Medicine's stock was trading at $8.87 at the start of the year. Since then, EDIT shares have decreased by 20.4% and is now trading at $7.06.
View the best growth stocks for 2023 here
.

Are investors shorting Editas Medicine?

Editas Medicine saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 20,640,000 shares, an increase of 7.7% from the February 28th total of 19,160,000 shares. Based on an average daily trading volume, of 1,740,000 shares, the days-to-cover ratio is presently 11.9 days.
View Editas Medicine's Short Interest
.

When is Editas Medicine's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our EDIT earnings forecast
.

How were Editas Medicine's earnings last quarter?

Editas Medicine, Inc. (NASDAQ:EDIT) announced its earnings results on Wednesday, February, 22nd. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.84) by $0.04. The company earned $6.54 million during the quarter, compared to analysts' expectations of $3.76 million. Editas Medicine had a negative trailing twelve-month return on equity of 50.28% and a negative net margin of 1,118.32%. The company's quarterly revenue was down 47.6% compared to the same quarter last year. During the same period last year, the firm posted ($0.61) earnings per share.

What other stocks do shareholders of Editas Medicine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Editas Medicine investors own include CRISPR Therapeutics (CRSP), NVIDIA (NVDA), Micron Technology (MU), Intellia Therapeutics (NTLA), Block (SQ), Advanced Micro Devices (AMD), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO) and Skyworks Solutions (SWKS).

When did Editas Medicine IPO?

(EDIT) raised $100 million in an IPO on Wednesday, February 3rd 2016. The company issued 5,900,000 shares at $16.00-$18.00 per share. Morgan Stanley and J.P. Morgan acted as the underwriters for the IPO and Cowen and Company and JMP Securities were co-managers.

What is Editas Medicine's stock symbol?

Editas Medicine trades on the NASDAQ under the ticker symbol "EDIT."

Who are Editas Medicine's major shareholders?

Editas Medicine's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Millennium Management LLC (3.12%), Dimensional Fund Advisors LP (2.40%), Geode Capital Management LLC (2.01%), JPMorgan Chase & Co. (1.72%), Credit Suisse AG (1.43%) and Two Sigma Investments LP (1.39%). Insiders that own company stock include Bruce Eaton, Charles Albright, Cynthia Collins, James C Mullen, Lisa Anne Michaels, Mark S Shearman and Michelle Robertson.
View institutional ownership trends
.

How do I buy shares of Editas Medicine?

Shares of EDIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Editas Medicine's stock price today?

One share of EDIT stock can currently be purchased for approximately $7.06.

How much money does Editas Medicine make?

Editas Medicine (NASDAQ:EDIT) has a market capitalization of $486.93 million and generates $19.71 million in revenue each year. The company earns $-220,430,000.00 in net income (profit) each year or ($3.21) on an earnings per share basis.

How many employees does Editas Medicine have?

The company employs 264 workers across the globe.

How can I contact Editas Medicine?

Editas Medicine's mailing address is 11 Hurley Street, Cambridge MA, 02141. The official website for the company is www.editasmedicine.com. The company can be reached via phone at (617) 401-9000 or via email at mark.mullikin@editasmed.com.

This page (NASDAQ:EDIT) was last updated on 3/30/2023 by MarketBeat.com Staff